FGF2 and non-small cell lung carcinoma: Earlier preclinical series had supported inhibitory activity against NSCLC for a number of different anti-FGF/FGFR therapies, including a bFGF-neutralizing monoclonal antibody, antisense oligonucleotides, or bFGF antisense cDNA-expressing vector in one study 25 and a dominant-negative FGFR1 IIIc-green fluorescent protein fusion protein or small molecule inhibitors in another study 53.